PALI PALISADE BIO INC

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition

Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic disease, today announced that it has been invited to present at the , being held November 19-21, 2024, in Boston, MA.

Details of the presentation details are as follows:

Title: Detailing Characteristics of Fibrostenotic Crohn’s Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy

Presenter: Mitch Jones, MD, PhD, Chief Medical Officer of Palisade Bio

Session: Examining the Latest Research & Development in Antifibrotic Research & Development

Date and Time: November 21, 2024 from 2:30-3:00 PM ET

The AFDD Summit is a leading forum for experts in the field of antifibrotic drug development, bringing together clinicians, researchers, and pharmaceutical leaders to discuss the latest advancements in treating fibrosis-related diseases. For more information about the AFDD Summit, please visit the .

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
14/11/2024

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Co...

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulati...

February 23, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Versto...

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon...

February 17, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets...

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that , will participate in a virtual fireside chat at the Piper Sandler Virtual N...

February 9, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life...

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that , will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Birou...

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisad...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch